Study on the efficacy and safety of Xueyou mixture in treating hemophilia

Chinese Journal of Integrative Medicine

Volumn 13, Issue 2, 2007, Pages 141-144

  Liu, Shan Xi ^a   Jiang, Lin ^a   Liu, Yi Guo ^a   He, Yue Qin ^a   Liang, Xin ^a   Kong, Wei Wei ^a   Chen, Jing ^a  

^a Shanxi YiDa Institute of Hematopathy   (China)

Author keywords

Hemophilia; Therapeutic efficacy; Xueyou mixture

Indexed keywords

BLOOD CLOTTING FACTOR; HERBACEOUS AGENT; SCATTER FACTOR; UNCLASSIFIED DRUG; XUEYOU MIXTURE;

ADOLESCENT; ADULT; ARTHROPATHY; ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CHILD; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEMATOMA; HEMOPHILIA; HUMAN; INFANT; LIVER DISEASE; LIVER PROTECTION; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEWBORN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; DRUGS, CHINESE HERBAL; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBINS; HEMOPHILIA A; HUMANS; INFANT; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED;

EID: 34447293319     PISSN: 16720415     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11655-007-0141-6     Document Type: Article

References (12)

1. Ye SG, editor. Internal medicine. 6th ed. Beijing: People' s Medical Publishing House, 2004:663-666.
2. Arruda VR, Schuettrumpf J, Herzog RW, et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype I. Blood 2004;103:85-92.
3. Follenzi A, Battaglia M, Lombardo A, et al. Targeting ientiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 2004; 103:3700-3709.
4. Gilles JG, Grailly SC, Maeyer M, et al. In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody. Blood 2004; 103(7):2617-2623.
5. Zhang ZN, editor. Standard for diagnosis and treatment of blood disease. 2nd ed. Beijing: Science Press, 1998:304-311.
6. Fay PJ, Jenkins PV. Mutating factor VIII: lessons from structure to function. Blood Rev 2005; 19:15-27.
7. Rodriguez MH, Plantier JL, Enjolras N, et al. Biosynthesis of FVIII in megakaryocytic cells: improved production and biochemical characterization. Br J Haematol 2004; 127:568-575.
8. Mohanty D, Ghosh K, Shetty S, et al. Mutations in the MCFD2 gene and a novel mutation in the LMAN 1 gene in Indian families with combined deficiency of factor V and VIII. Am J Hematol 2005; 79:262-266.
9. Nakaya SM, Hsu TC, Geraghty SJ, et al. Severe hemophilia A due to a 1.3 kb factor VIII gene deletion including exon24: homologous recombination between 41 bp within an Alu repeat sequence in introns 23 and 24. J Thromb Haemost 2004;2:1941-1945.
10. Spiegel PC, Murphy P, Stoddard BL. Surface-exposed hemophilic mutations across the factor VIIIC2 domain have variable effects on stability and binding activities. J Biol Chem 2004; 279:53691-53698.
11. Nogami K, Freas J, Manithody C, et al. Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain. J Biol Chem 2004; 279:33104-33113.
12. Shen PA, editor. Traditional Chinese medicine pharmacology and clinical appliance. Beijing: People' s Medical Publishing House, 2006: 75-80, 95-98, 829-832, 822-825.